Arcticzymes Technologies Asa · OSL:AZT
Arcticzymes Technologies Asa — Q4 2020 Earnings Presentation
20 slides from Arcticzymes Technologies Asa's earnings presentation, 2021
Slide 1: ArcticZymes Technologies
A ArcticZymes Technologies
Slide 2: Agenda
Agenda 1 Highlights Q4 2020 2 ArcticZymes Update 3 BetaGlucans Divestment 4 Q4 Financials 5 Outlook 2021 and Beyond
Slide 3: Highlights
Highlights
Slide 4: Highlights Q4 2020
Highlights Q4 2020 Company has undergone a significant transformation Achieved 2nd best ArcticZymes Therapeutics and quarterly Technologies molecular segments performance – 22.1 becomes a pure continue to grow MNOK sales* enzymes company Achieved another Biotec BetaGlucans profitable quarter – succe
Slide 5: Deliverables 2020
Deliverables 2020 All about value creation Achieved profitability: 45 MNOK EBITDA Sale growth achieved: 93 MNOK Rebranded company to ArcticZymes Technologies Became a pure enzyme company by divesting BBG Created shareholder value through the share Merger & acquisition – not achieved 5
Slide 6: ArcticZymes Update
ArcticZymes Update
Slide 7: Commercial Segment Sales: Therapeutics, Research & Diagnostics
ArcticZymes Updates Commercial Segment Sales Therapeutics Research & Diagnostics ✓ Strong quarterly growth ✓ Marginal quarterly growth ✓ 41% contribution to total Q4 sales ✓ 59% contribution to total Q4 sales ✓ Several customers: purchased >5 MNOK of products ✓ Molecular diagnostics (MDx) sales is m
Slide 8: Coronavirus related sales
ArcticZymes Updates Coronavirus related sales Integral part of underlying business Coronavirus related sales higher for Q4 vs. Q3 32% contribution of total Q4 sales Coronavirus related sales breakdown: 86% associates with MDx 14% associates with Therapeutics Quarterly fluctuations to continue
Slide 9: Innovation Pipeline
ArcticZymes Update Innovation Pipeline Salt Active Nuclease Upscaling* First medium-scale pilot production batch was successful Working on first large-scale pilot batch Large scale SAN-HQ product commercially available within H1 2021 Anticipate several new products will be ready to launch in 2021 M-
Slide 10: Strategic Growth Initiatives
ArcticZymes Update Strategic Growth Initiatives Organic Growth Represents main and immediate focus Key activity for 2021 will be to complete the infrastructure expansion of R&D and operations The project is well underway and progressing as planned Continue to invest in new R&D and operational person
Slide 11: BetaGlucans Divestment
BetaGlucans Divestment
Slide 12: Biotec BetaGlucans (BBG)
Biotec BetaGlucans (BBG) Divesture successfully closed Entire BBG subsidiary divested to Lallemand Inc´s subsidiary, Danstar Ferment AG Deal was closed on 31st December 2020 ArcticZymes Technologies will support Lallemand during 2021 in managing a smooth transition BBG will gradually relocated to th
Slide 13: Q4 Financials
Q4 Financials
Slide 14: Sales Q4 2020
ArcticZymes Sales Q4 2020 Positive development Sales per segment Amounts in NOK 1.000' Sales growth of 35% compared to same 40 000 quarter last year 35 000 Therapeutics (SAN) Research and Diagnostics Therapeutics segment (SAN) continues to 30 000 deliver strong sales: 9.0 MNOK (3.8) 25 000 Underlyin
Slide 15: Sales Q4 2020: Covid-19 impact
ArcticZymes Sales Q4 2020 Covid-19 impact is estimated at 28%of annual sales Estimated Covid-19 related sales Amounts in NOK 1.000' 12 000 10 000 8 000 6 000 4 000 2 000 - Q1 2020 Q2 2020 Q3 2020 Q4 2020 15
Slide 16: Growth in sales and expenses
ArcticZymes Technologies Growth in sales and expenses Amounts in NOK 1.000' 36 000 35% improvement in sales (MNOK 22.1 vs 16.3) 39% improvement in EBITDA (MNOK 6.8 vs 4.9) 31 000 Sales EBITDA 26 000 Expenses increased by 3.9 MNOK 21 000 Increase in personnel Divestment related expenses 16 000 Increa
Slide 17: Cash Flow
Cash Flow Divestment of BBG contributed with 70 MNOK in Q4 Cash position 140 000 90 000 80 000 120 000 Amounts in NOK Net1.000' Cash Changes in Cash 70 000 100 000 60 000 50 000 Changes in Cash 80 000 Net Cash 140 178 40 000 30 000 60 000 20 000 40 000 10 000 59 939 48 439 - 31 580 31 290 20 000 28
Slide 18: Outlook 2021 & Beyond
Outlook 2021 & Beyond
Slide 19: Outlook 2021 and Beyond
Outlook 2021 and Beyond A new era as a pure enzymes company Performance Focus on topline sales growth New Innovations Profitability Becoming Europe’s leading one-stop- Focus remains on increasing shop enzyme supplier in next 2-3 years profitability Investment Expanded facilities as well as talented
Slide 20: Thank you!
Thank you! arcticzymes.com
ArcticZymes Technologies — Q4 2020 Earnings Presentation on 6ix